3D Cancer Models from fresh patient tissue: Accuracy that drives success

Make better decisions for your translational immuno-oncology program with the most clinically-relevant patient model of the tumor microenvironment (TME)—a 3D cancer model unlike any other.  

VIEW VIDEO

Our Technology

Nilogen’s patented tumoroid technology is a 3D cancer model that captures the full heterogeneity of an individual tumor—including intact TME—in each well, enabling a more accurate understanding of therapeutic response.

logo
Retains Intact TME

Up to 9,000 tumoroids are created from each patient’s tumor using minimal processing, retaining an intact TME.

logo
Captures full tumor heterogeneity

Tumoroids from each patient’s tumor are pooled so that an aliquot in each well represents the heterogeneity of the complete tumor.

logo
Reflects clinical response rate

Nilogen’s tumoroid technology captures similar patient response rates to those seen in the clinic.

Immuno-Oncology Applications

Immuno-Oncology Applications

icons-antibody-based-therapeutics
Antibody Based Therapeutics

Elucidate mechanism of action, quantify tumor cell killing, and evaluate multiple drug combinations in the same patient tissue.

icons-cell-therapie
Cell Therapies

Assess tumor penetration, evaluate the impact on the TME, and accurately quantify tumor cell killing.

icons-oncolytic-viruses
Oncolytic virus

Gain detailed, quantitative insight into oncolytic virus penetration, replication and tumor cell killing.

Nilogen Services

We deliver so much more than data. Our 3D-EXplore 3D cancer model platform uses the latest analytical technologies combined with advanced bioinformatics and artificial intelligence algorithms to provide you with fully interpreted, highly actionable insight to drive accurate decision making for your drug development programs. 

High Content Imaging

services-high-content-imaging@2x[1]

We use advanced confocal platforms for high resolution, quantitative imaging

  • Quantify tumor cell killing
  • Quantify penetration distance into the TME
  • Evaluate Phagocyotosis

Flow Cytometry

services-flow-cytometry@2x[1]

Our expert team delivers insight from our multiparameter flow cytometric technologies

  • Multiple, optimized, pre-designed or customized panels
  • Fully customizable panels
  • Multiplex up to 14 fluorophores in each panel

Gene Expression and Proteomics Analysis

services-proteogenomics-analysis@2x[1]

We offer a full range of next generation sequencing (NGS) and proteogenomics analysis with the latest technologies

  • Single cell RNA-seq (10X Genomics Platform)
  • Single cell CITE-seq (BioLegend's TOTALseq Platform)
  • Nanostring PanCancer & IO 360 Gene Expression Panels
  • Custom bioinformatics and other analysis available

Multiplex Cytokine Assays

services-multiplex-ca@2x[1]

We use the BioRad BioPlex 200 for the simultaneous analysis of up to 100 cytokines and chemokines

  • Highly quantitative
  • Pre-designed optimised panels
  • Panel customisation available

About Nilogen

At Nilogen, our mission is to improve the treatment and quality of life for cancer patients by helping companies develop oncology therapies of the future by improving their chance of success in clinical trials through the application of game-changing human tumor tissue assays which provide a comprehensive analysis of drug impact on the immune compartment as well as tumor cells

about-us

Latest Articles

Searching for the proverbial needle in a haystack. Biomarkers unleashed.
artical1
Why intact TME is essential for oncology drug development
artical1
Why Tumoroids are not tumor organoids
artical1

Latest News

Discover the latest highlights and news releases from Nilogen.

Nilogen Oncosystems announces the appointment of Eolas Biosciences as its exclusive business partner in Japan for marketing the 3D-EXplore tumoroid platform

April 1, 2021

Nilogen to publish 3 new posters at AACR 2021